Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
BioOptics Stock Watch
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Moderna, Inc. - Common Stock
(NQ:
MRNA
)
43.98
+3.87 (+9.65%)
Streaming Delayed Price
Updated: 11:47 AM EST, Feb 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Moderna, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Moderna (MRNA) Q4 2025 Earnings Call Transcript
↗
Today 9:39 EST
Moderna (MRNA) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Moderna Inc (NASDAQ:MRNA) Beats Q4 2025 Estimates Amid Post-Pandemic Transition
↗
Today 8:22 EST
Via
Chartmill
Moderna (NASDAQ:MRNA) Exceeds Q4 CY2025 Expectations
Today 7:11 EST
Biotechnology company Moderna (NASDAQ:MRNA) beat Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 29.8% year on year to $678 million. Its GAAP loss of $2.11 per share was 18.9% above...
Via
StockStory
Topics
Artificial Intelligence
Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates
Today 7:00 EST
Via
ACCESS Newswire
Nasdaq, S&P 500 Futures Edge Lower Ahead Of CPI Data: Why NVDA, AAPL, TSLA, RIVN, MRNA, AMAT, IREN Are On Traders' Radar Today
↗
Today 4:07 EST
Data on Stocktwits showed retail traders remained bearish on SPY and ‘extremely bearish’ on QQQ.
Via
Stocktwits
Topics
Bonds
ETFs
Economy
Moderna: Stock to Avoid or Bad News Buy?
↗
February 12, 2026
Moderna stock was a highflier in early pandemic days as sales of its coronavirus vaccine soared.
Via
The Motley Fool
FDA Stuns Moderna with Refusal to Review Flu Vaccine, Sending Shares Tumbling 3.5%
February 12, 2026
Shares of Moderna, Inc. (NASDAQ: MRNA) fell 3.5% on February 12, 2026, as investors continued to digest the fallout from a rare and unexpected regulatory setback. The U.S. Food and Drug Administration...
Via
MarketMinute
Topics
Earnings
The Bioelectronic Frontier: A Deep-Dive into NovoCure’s Multi-Indication Transformation
February 12, 2026
The following research article examines NovoCure Limited (NASDAQ: NVCR) through a deep-dive lens, focusing on its pioneering role in bioelectronic oncology and its current strategic pivot as of...
Via
Finterra
Topics
Initial Public Offering
Intellectual Property
AI Agents and the Jobs Report Jitter: A Wall Street Balancing Act
↗
February 12, 2026
Via
Chartmill
Topics
Artificial Intelligence
What To Expect From Moderna’s (MRNA) Q4 Earnings
February 11, 2026
Biotechnology company Moderna (NASDAQ:MRNA) will be reporting results this Friday before market hours. Here’s what to look for.
Via
StockStory
Topics
Artificial Intelligence
Exploring the top movers within the S&P500 index during today's session.
↗
February 11, 2026
Via
Chartmill
Gapping S&P500 stocks in Wednesday's session
↗
February 11, 2026
Via
Chartmill
Moderna (MRNA) Deep Dive: Navigating Regulatory Blows and the Pivot to Oncology
February 11, 2026
Today, February 11, 2026, marks a volatile chapter for Moderna, Inc. (NASDAQ: MRNA). The biotechnology pioneer, which became a household name during the COVID-19 pandemic, finds itself at a critical...
Via
Finterra
Topics
Artificial Intelligence
Initial Public Offering
Intellectual Property
These S&P500 stocks are moving in today's pre-market session
↗
February 11, 2026
Via
Chartmill
Nasdaq, S&P 500 Futures Rise Ahead Of Delayed Jobs Data: Why NVDA, WBD, HOOD, MRNA, ASTS Are On Traders' Radar Today
↗
February 11, 2026
Retail chatter on Stocktwits shows that sentiment remains deeply bearish on SPY and QQQ.
Via
Stocktwits
Topics
Artificial Intelligence
ETFs
Stocks
Why Did Moderna Stock Tumble Nearly 10% After Hours Today?
↗
February 10, 2026
The FDA’s CBER issued a refusal-to-file letter for Moderna’s flu vaccine mRNA-1010.
Via
Stocktwits
Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
February 10, 2026
Via
ACCESS Newswire
1 Reason I'd Buy Vertex Pharmaceuticals Stock and Never Sell
↗
February 10, 2026
Vertex stock has climbed more than 60% over three years.
Via
The Motley Fool
Topics
Intellectual Property
Stay informed with the top movers within the S&P500 index on Tuesday.
↗
February 10, 2026
Via
Chartmill
Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico
February 10, 2026
Via
ACCESS Newswire
Should You Buy Moderna Before Feb. 13?
↗
February 09, 2026
The biotech has momentum as its quarterly report approaches.
Via
The Motley Fool
Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model
February 06, 2026
As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a...
Via
Finterra
Topics
ETFs
Economy
Initial Public Offering
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
February 05, 2026
Issued on behalf of Oncolytics Biotech Inc.
From
Equity Insider
Via
GlobeNewswire
Tom Gardner's 2026 Outlook: Volatility, Government Scrutiny, and Two AI-Adjacent Stocks
↗
February 04, 2026
Tom Gardner outlines two selective AI opportunities and a disciplined portfolio framework for the next three to five years.
Via
The Motley Fool
Topics
Artificial Intelligence
Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc.
February 04, 2026
From
Defiance ETFs
Via
GlobeNewswire
Gapping S&P500 stocks in Monday's session
↗
February 02, 2026
Via
Chartmill
Explore the top gainers and losers within the S&P500 index in today's session.
↗
January 30, 2026
Via
Chartmill
Dr. David Berman to Join Moderna as Chief Development Officer
January 30, 2026
Via
ACCESS Newswire
Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)
January 29, 2026
Via
ACCESS Newswire
3 ETFs Catapulting Beyond the S&P to Start the Year
↗
January 29, 2026
Via
MarketBeat
Topics
ETFs
Stocks
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
